Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Pluri Inc. (PLUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PLUR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.05% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.69M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.76 | 52 Weeks Range 3.33 - 7.13 | Updated Date 08/29/2025 |
52 Weeks Range 3.33 - 7.13 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1264.64% |
Management Effectiveness
Return on Assets (TTM) -36.57% | Return on Equity (TTM) -1833.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 45607845 | Price to Sales(TTM) 39.36 |
Enterprise Value 45607845 | Price to Sales(TTM) 39.36 | ||
Enterprise Value to Revenue 44.11 | Enterprise Value to EBITDA -1.28 | Shares Outstanding 7871150 | Shares Floating 3861237 |
Shares Outstanding 7871150 | Shares Floating 3861237 | ||
Percent Insiders 43.41 | Percent Institutions 19.65 |
Upturn AI SWOT
Pluri Inc.
Company Overview
History and Background
Pluri Inc., founded in 2003, is a biotechnology company focused on cell therapy technology and regenerative medicine. It has developed a proprietary technology platform for the mass production of placenta-derived cells.
Core Business Areas
- Cell Therapy: Development and commercialization of cell therapy products for various medical conditions, including hematologic malignancies, acute radiation syndrome, and muscle regeneration.
Leadership and Structure
Pluri Inc. is led by a management team with expertise in biotechnology, clinical development, and commercialization. The company operates with a structured organizational framework focusing on research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- PLX-R18: PLX-R18 is Pluri's lead product candidate, developed as a cell therapy for the treatment of Acute Radiation Syndrome (ARS) and incomplete hematopoietic recovery following hematopoietic cell transplantation. Market share data is currently unavailable as it's in development. Competitors include companies developing supportive care therapies for ARS.
Market Dynamics
Industry Overview
The cell therapy and regenerative medicine industry is experiencing significant growth, driven by advancements in technology and increasing demand for novel therapies for unmet medical needs.
Positioning
Pluri Inc. is positioned as an innovative cell therapy company leveraging its proprietary technology platform. Its competitive advantage lies in its placenta-derived cell technology.
Total Addressable Market (TAM)
The TAM for cell therapies is projected to reach billions of dollars in the coming years. Pluri Inc. aims to capture a portion of this market through its lead product candidates and future developments.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform for cell production
- Potential for broad therapeutic applications
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Relatively small company
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increased government funding for regenerative medicine
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- Vertex Pharmaceuticals (VRTX)
- bluebird bio (BLUE)
- CRISPR Therapeutics (CRSP)
Competitive Landscape
Pluri faces competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. Pluri's competitive edge hinges on the unique properties of its placenta-derived cells.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by R&D progress and clinical trial advancements.
Future Projections: Future growth is projected based on successful clinical trials and potential commercialization of PLX-R18.
Recent Initiatives: Recent initiatives include advancement of PLX-R18 in clinical trials and exploration of new therapeutic applications.
Summary
Pluri Inc. is a developmental stage biotechnology company with potential in cell therapy due to its unique technology. Its success depends heavily on the success of its clinical trials, particularly PLX-R18. The company needs to secure further funding. The high potential in the industry means it faces strong competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Pluri Inc. Investor Relations
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pluri Inc.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2003-06-30 | President, CEO & Director Mr. Yaacov Yanay | ||
Sector Healthcare | Industry Biotechnology | Full time employees 106 | Website https://www.pluri-biotech.com |
Full time employees 106 | Website https://www.pluri-biotech.com | ||
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, is composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and phase I trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services; cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food-tech, CDMO, and agtech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.